204 related articles for article (PubMed ID: 19233569)
21. Influence of the MDM2 single nucleotide polymorphism SNP309 on tumour development in BRCA1 mutation carriers.
Copson ER; White HE; Blaydes JP; Robinson DO; Johnson PW; Eccles DM
BMC Cancer; 2006 Mar; 6():80. PubMed ID: 16563154
[TBL] [Abstract][Full Text] [Related]
22. Role of the MDM2 promoter polymorphism (-309T>G) in acute myeloid leukemia development.
Cingeetham A; Vuree S; Jiwatani S; Kagita S; Dunna NR; Meka PB; Gorre M; Annamaneni S; Digumarti R; Sinha S; Satti V
Asian Pac J Cancer Prev; 2015; 16(7):2707-12. PubMed ID: 25854351
[TBL] [Abstract][Full Text] [Related]
23. MDM2 gene polymorphisms and risk of classic Kaposi's sarcoma among Iranian patients.
Varmazyar S; Marashi SM; Shoja Z; Tornesello ML; Buonaguro FM; Shahmahmoodi S; Safaie-Naraghi Z; Jalilvand S
Med Microbiol Immunol; 2017 Apr; 206(2):157-163. PubMed ID: 28083704
[TBL] [Abstract][Full Text] [Related]
24. Effect of MDM2 SNP309 and p53 codon 72 polymorphisms on lung cancer risk and survival among non-smoking Chinese women in Singapore.
Chua HW; Ng D; Choo S; Lum SS; Li H; Soh LY; Sabapathy K; Seow A
BMC Cancer; 2010 Mar; 10():88. PubMed ID: 20219101
[TBL] [Abstract][Full Text] [Related]
25. Combined effects of p53 and MDM2 polymorphisms on susceptibility and surgical prognosis in hepatitis B virus-related hepatocellular carcinoma.
Yang Y; Xia T; Li N; Zhang J; Yang Y; Cong W; Deng Q; Lan K; Zhou W
Protein Cell; 2013 Jan; 4(1):71-81. PubMed ID: 23292895
[TBL] [Abstract][Full Text] [Related]
26. Impacts of human leukocyte antigen DQ genetic polymorphisms and their interactions with hepatitis B virus mutations on the risks of viral persistence, liver cirrhosis, and hepatocellular carcinoma.
Ji X; Zhang Q; Li B; Du Y; Yin J; Liu W; Zhang H; Cao G
Infect Genet Evol; 2014 Dec; 28():201-9. PubMed ID: 25281206
[TBL] [Abstract][Full Text] [Related]
27. MDM2 309T>G polymorphism and risk of squamous cell carcinomas of head and neck: a meta-analysis.
Liu J; Zheng Y; Lei D; Liu D; Xu F; Jin T; Cao X; Zhao X; Yu X; Pan X
Asian Pac J Cancer Prev; 2011; 12(8):1899-903. PubMed ID: 22292622
[TBL] [Abstract][Full Text] [Related]
28. Influence of MDM2 SNP309 and SNP285 status on the risk of cancer in the breast, prostate, lung and colon.
Gansmo LB; Knappskog S; Romundstad P; Hveem K; Vatten L; Lønning PE
Int J Cancer; 2015 Jul; 137(1):96-103. PubMed ID: 25431177
[TBL] [Abstract][Full Text] [Related]
29. Genetic polymorphisms of MDM2, cumulative cigarette smoking and nonsmall cell lung cancer risk.
Liu G; Wheatley-Price P; Zhou W; Park S; Heist RS; Asomaning K; Wain JC; Lynch TJ; Su L; Christiani DC
Int J Cancer; 2008 Feb; 122(4):915-8. PubMed ID: 17957785
[TBL] [Abstract][Full Text] [Related]
30. Mdm2 SNP309 G-variant is associated with invasive growth of human urinary bladder cancer.
Hitzenbichler F; Stoehr CG; Rogenhofer M; Wieland WF; Ruemmele P; Hartmann A; Stoehr R
Pathobiology; 2014; 81(2):53-9. PubMed ID: 24217660
[TBL] [Abstract][Full Text] [Related]
31. Associations of MDM2 SNP309, transcriptional activity, mRNA expression, and survival in stage I non-small-cell lung cancer patients with wild-type p53 tumors.
Chien WP; Wong RH; Cheng YW; Chen CY; Lee H
Ann Surg Oncol; 2010 Apr; 17(4):1194-202. PubMed ID: 19941079
[TBL] [Abstract][Full Text] [Related]
32. Association between MDM2 SNP309, p53 Arg72Pro, and hepatocellular carcinoma risk: A MOOSE-compliant meta-analysis.
Duan X; Li J
Medicine (Baltimore); 2017 Sep; 96(36):e7856. PubMed ID: 28885338
[TBL] [Abstract][Full Text] [Related]
33. Lack of association between the MDM2-SNP309 polymorphism and breast cancer risk.
Petenkaya A; Bozkurt B; Akilli-Ozturk O; Kaya HS; Gur-Dedeoglu B; Yulug IG
Anticancer Res; 2006; 26(6C):4975-7. PubMed ID: 17214373
[TBL] [Abstract][Full Text] [Related]
34. Association of breast cancer outcome with status of p53 and MDM2 SNP309.
Boersma BJ; Howe TM; Goodman JE; Yfantis HG; Lee DH; Chanock SJ; Ambs S
J Natl Cancer Inst; 2006 Jul; 98(13):911-9. PubMed ID: 16818855
[TBL] [Abstract][Full Text] [Related]
35. MDM2 SNP309 accelerates breast and ovarian carcinogenesis in BRCA1 and BRCA2 carriers of Jewish-Ashkenazi descent.
Yarden RI; Friedman E; Metsuyanim S; Olender T; Ben-Asher E; Papa MZ
Breast Cancer Res Treat; 2008 Oct; 111(3):497-504. PubMed ID: 18026875
[TBL] [Abstract][Full Text] [Related]
36. Contribution of Murine Double Minute 2 Genotypes to Colorectal Cancer Risk in Taiwan.
Yueh TC; Hung YW; Shih TC; Wu CN; Wang SC; Lai YL; Hsu SW; Wu MH; Fu CK; Wang YC; Ke TW; Chang WS; Tsai CW; Bau DT
Cancer Genomics Proteomics; 2018; 15(5):405-411. PubMed ID: 30194081
[TBL] [Abstract][Full Text] [Related]
37. Murine double minute clone 2,309T/G and 285G/C promoter single nucleotide polymorphism as a risk factor for breast cancer: a Polish experience.
Piotrowski P; Lianeri M; Rubis B; Knuła H; Rybczyńska M; Grodecka-Gazdecka S; Jagodziński PP
Int J Biol Markers; 2012 Jul; 27(2):e105-10. PubMed ID: 22467100
[TBL] [Abstract][Full Text] [Related]
38. No association between MDM2 SNP309 promoter polymorphism and basal cell carcinoma of the skin.
Wilkening S; Hemminki K; Rudnai P; Gurzau E; Koppova K; Försti A; Kumar R
Br J Dermatol; 2007 Aug; 157(2):375-7. PubMed ID: 17553029
[TBL] [Abstract][Full Text] [Related]
39. Genotypic interaction and gender specificity of common genetic variants in the p53/mdm2 network in Crohn's disease.
Zimmer V; Widmann T; Müller M; Ong MF; Stein JM; Pfreundschuh M; Lammert F; Roemer K; Assmann G
Digestion; 2010; 81(4):246-51. PubMed ID: 20110711
[TBL] [Abstract][Full Text] [Related]
40. Association of rheumatoid arthritis with Mdm2 SNP309 and genetic evidence for an allele-specific interaction between MDM2 and p53 P72R variants: a case control study.
Assmann G; Voswinkel J; Mueller M; Bittenbring J; Koenig J; Menzel A; Pfreundschuh M; Roemer K; Melchers I
Clin Exp Rheumatol; 2009; 27(4):615-9. PubMed ID: 19772793
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]